Various surrogate endpoints for overall survival (OS) have been recently used by FDA for drug approval in miscellaneous cancer types. This aims to facilitate the establishment of clinical trials, propose beneficial treatment options after shorter duration of assessment and provides new clinical prognostic tools. Metastasis-Free Survival (MFS) has been proven to be a Strong Surrogate for Overall Survival in Localized Prostate Cancer. However, this surrogacy has not been studied in breast cancer or any other solid tumor.
AIM OF THE WORK:
To determine the prognostic value of metastasis free interval (MFI) to be a surrogate for overall survival after metastasis in female patients with metastatic breast cancer and To compare MFIamong the Breast cancer subtypes in metastatic breast cancer female patients.
Patients and Methods:
Patients
This retrospective study included 332 breast cancer female patients whose data was retrieved from the archives of medical research institute from December 2009 to December 2019. All included patients had an initial diagnosis of stage 1–3 breast cancer and all have developed subsequent distant metastasis.